Evidence map›Paper›PMID 42613183›Full record

Observational studyAnnals of laboratory medicine2026

Prognostic Impact of Sequential Measurable Residual Disease and

Ting-Chi Yeh, Tang-Her Jaing, Hsi-Che Liu, Shih-Hsiang Chen, Shih-Chung Wang, Chih-Cheng Hsiao, Shyh-Shin Chiou, Jen-Yin Hou, Pei-Chin Lin, Fang-Liang Huang and 4 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ting-Chi YehDivision of Pediatric Hematology-Oncology, Mackay Children's Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0003-0437-3130
Tang-Her JaingDivision of Pediatric Hematology-Oncology, Chang Gung Children's Hospital, Linkou, Taoyuan, Taiwan.ORCID https://orcid.org/0000-0002-5407-1555
Hsi-Che LiuDivision of Pediatric Hematology-Oncology, Mackay Children's Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-9721-167X
Shih-Hsiang ChenDivision of Pediatric Hematology-Oncology, Chang Gung Children's Hospital, Linkou, Taoyuan, Taiwan.ORCID https://orcid.org/0000-0003-2588-2735
Shih-Chung WangDivision of Pediatric Hematology-Oncology, Changhua Christian Children's Hospital, Changhua, Taiwan.ORCID https://orcid.org/0000-0001-7882-7276
Chih-Cheng HsiaoDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0002-3269-521X
Shyh-Shin ChiouDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0001-7639-9116
Jen-Yin HouDivision of Pediatric Hematology-Oncology, Mackay Children's Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-0716-0838
Pei-Chin LinDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0003-3895-9500
Fang-Liang HuangDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.ORCID https://orcid.org/0000-0002-4743-9788
Shang-Hsien YangDivision of Pediatric Hematology-Oncology, Department of Pediatrics, Hualien Tzu Chi General Hospital, Hualien, Taiwan.ORCID https://orcid.org/0000-0003-3676-2595
Ting-Yu HuangDivision of Hematology-Oncology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.ORCID https://orcid.org/0009-0001-2414-9497
Chao-Ping YangDivision of Pediatric Hematology-Oncology, Chang Gung Children's Hospital, Linkou, Taoyuan, Taiwan.ORCID https://orcid.org/0009-0001-4396-6775
Lee-Yung ShihDivision of Hematology-Oncology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.ORCID https://orcid.org/0000-0003-1866-7922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although measurable residual disease (MRD) is an established prognostic marker in pediatric acute myeloid leukemia (AML), its dynamic prognostic value during treatment and its integration with the Methods: We retrospectively analyzed 112 children with CBF-AML. We assessed MRD in bone marrow samples collected at diagnosis, the end of induction (EOI), the end of second consolidation (EO2C), and the end of consolidation (EOC) using quantitative reverse transcription PCR with TaqMan assays targeting two fusion transcripts. Results: In Conclusions: Our findings highlight the importance of sequential MRD monitoring in pediatric patients with

Indexed as

Leukemia, Myeloid, AcuteProto-Oncogene Proteins c-kitAdolescentChildChild, PreschoolCore Binding Factor Alpha 2 SubunitCore Binding FactorsDisease-Free SurvivalFemaleHumansInfantMaleNeoplasm, ResidualOncogene Proteins, FusionPrognosisRetrospective StudiesCore Binding Factor Alpha 2 SubunitCore Binding FactorsKIT protein, humanOncogene Proteins, FusionProto-Oncogene Proteins c-kitRUNX1 protein, humanRUNX1T1 protein, humanRUNX1 Translocation Partner 1 ProteinChildrenCore-binding factorLeukemiaMeasurable residual diseaseOncology

Identifiers

PMID42613183
PMCPMC13662482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.